The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...

Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

China's National Health Commission plans to address gaps in mental health services from 2025-2027, focusing on youth. Eli ...

Even the coroner specified that the self-inflicted death was an “adverse effect” of the antidepressant the man had been ...

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials ...

Research shows that caffeine inhibits the action of some antibiotics, such as Avelox (moxifloxacin), Noroxin (norfloxacin), ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...